Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...